Abstract 1744P
Background
Patients with colon cancer from more deprived areas may face barriers to accessing timely, quality healthcare. These barriers may contribute to socioeconomic inequalities in survival. We examined differences in treatment and time to diagnosis and treatment between socioeconomic groups.
Methods
The English Cancer Registry identified a retrospective cohort of patients diagnosed with colon cancer in England between 2016-2017. Cancer Registry data were linked to Hospital Episode Statistics, Cancer Pathway, Systematic Anti-Cancer Dataset and Diagnostic Imaging Datasets. Lasso logistic regression identified predictors of colon cancer treatment. The secondary care diagnostic interval (SCDI) was used to calculate the time to diagnosis and treatment, analysed using quantile regression. All analyses were conducted using STATA. The study was registered on ClinicalTrials.gov (NCT05185388).
Results
A total of 35,248 patients were included in the analyses. Area deprivation was a significant predictor of receipt of surgery and chemotherapy. The adjusted odds of treatment were reduced for patients from the most deprived quintile: surgery (OR 0.78), chemotherapy in stage IV (OR 0.88), and chemotherapy in stage II-III (OR 0.79). The median SCDI was 20 days for patients from the most and least deprived areas. However, patients from the most deprived area had a significantly longer time to diagnosis after adjusting for other factors (median difference 0.73 days [95% CI 0.09-1.36]). Meanwhile, the median treatment interval was 55 and 57 days for patients from the least and most deprived areas, respectively. The treatment interval was significantly longer for patients from the most, compared with the least deprived areas after adjusting for important factors (median difference 2.29 days [95% CI 1.28-3.31]).
Conclusions
In this large cohort of patients with colon cancer in England, we demonstrated that patients from more deprived areas are less likely to receive surgery or chemotherapy and wait longer to commence treatment. Further research is needed to understand why and what evidence-based actions can reduce these inequalities in treatment and timeliness.
Clinical trial identification
NCT05185388.
Editorial acknowledgement
Legal entity responsible for the study
University of Hull.
Funding
Yorkshire Cancer Research.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1912TiP - STELLAR-304: A randomized phase III study of zanzalintinib (XL092) and nivolumab in non-clear cell renal cell carcinoma (nccRCC)
Presenter: Sumanta Pal
Session: Poster session 23
2366P - Phase I-II study of niraparib plus cabozantinib in patients with advanced urothelial/kidney cancer (NICARAGUA trial)
Presenter: Daniel Castellano Gauna
Session: Poster session 23
2367P - A randomized phase II study of atezolizumab (atezo) plus recombinant human IL-7 (CYT107) vs. atezo alone in patients with locally advanced or metastatic urothelial carcinoma (mUC)
Presenter: Russells Pachynski
Session: Poster session 23
2368P - Activity of cabozantinib (CABO) plus durvalumab (DURVA) in patients (pts) with advanced non-urothelial-carcinoma variant histologies (VHs) or urothelial carcinoma (UC) after platinum-based chemotherapy: Interim results from the phase II ARCADIA trial
Presenter: Patrizia Giannatempo
Session: Poster session 23
2369P - Phase II study of nivolumab (nivo) and ipilimumab (ipi) for advanced bladder cancer with variant histologies (BCVH)
Presenter: Bradley McGregor
Session: Poster session 23
2370P - Updated results of PEANUT trial: Pembrolizumab and nab-paclitaxel as salvage therapy for platinum-treated, locally advanced or metastatic urothelial carcinoma (mUC)
Presenter: Achille Bottiglieri
Session: Poster session 23
2371P - Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC): Long-term outcomes from the JAVELIN Bladder 100 trial in older patients (pts)
Presenter: Shilpa Gupta
Session: Poster session 23
2372P - Efficacy of a tailored approach with nivolumab (N) and nivolumab+ipilimumab (N+I) as immuno-therapeutic boost in metastatic urothelial carcinoma (mUC): Final results of TITAN-TCC
Presenter: Marc-Oliver Grimm
Session: Poster session 23
2373P - Outcomes by retrospective eligibility for maintenance therapy of patients (pts) with advanced urothelial carcinoma (UC): Post hoc analysis of KEYNOTE-361
Presenter: Ronac Mamtani
Session: Poster session 23
2374P - A phase Ib single-arm trial of bintrafusp alfa (BA) for pretreated, locally advanced/unresectable or metastatic (advanced) urothelial cancer (aUC)
Presenter: Petros Grivas
Session: Poster session 23